MYC and cancer: Moreover, the redundancy of MYC dosage compensation—mediated by at least three different miRNAs from the miR-17/92 cluster [8] requires the development of specialized strategies capable of simultaneously inhibiting multiple miRNAs while ensuring selective cytotoxicity in MYC-amplified cancer cells.